Receive our newsletter – data, insights and analysis delivered to you
  1. News
April 3, 2016updated 19 Nov 2018 2:52pm

Sandoz Canada launches new respiratory antibiotic

Sandoz Canada has expanded its product range with the introduction of a new respiratory antibiotic, Tobramycin inhalation solution.

Sandoz Canada has expanded its product range with the introduction of a new respiratory antibiotic, Tobramycin inhalation solution.

The medicine is an authorised generic version of Tobi that is currently marketed by Novartis Pharmaceuticals Canada.

It is suggested for the management of cystic fibrosis patients with chronic pulmonary Pseudomonas aeruginosa (P aeruginosa) infections.

Cystic fibrosis is a life-threatening genetic disease that primarily affects the lungs and digestive system.

Sandoz Canada president Michel Robidoux said: "We are proud to bring an authorised generic version of Tobi to Canadian patients with cystic fibrosis and suffering from chronic pulmonary infections.

"This launch is in line with our commitment to offer high-quality, affordable medicines in order to facilitate patient access to healthcare."

Content from our partners
Extractables and leachables analysis in pharmaceutical quality control
How Hengst helped to keep Germany’s charity “star singers” shining
"We are proud to bring an authorised generic version of Tobi to Canadian patients with cystic fibrosis and suffering from chronic pulmonary infections."

Sandoz’s Tobramycin inhalation solution is a formulation of Tobramycin that is designed specifically for administration by inhalation.

Tobramycin is an aminoglycoside antibiotic derived from Streptomyces tenebrarius and is used to treat various types of bacterial infections.

When the medicine is inhaled, tobramycin can be detected at high concentrations in the sputum of cystic fibrosis patients. It is a cationic polar molecule that does not readily cross epithelial membranes and is chemically and pharmacologically related to the aminoglycoside class of antibiotics.

According to the company, the respiratory antibiotic’s primary mode of action is bactericidal resulting from disruption of protein synthesis in susceptible bacteria.

The safety and efficacy of the medicine was evaluated in two identically designed, double-blind, randomised, placebo-controlled 24-week clinical studies at 69 cystic fibrosis centres in the US.

Figures released by Cystic Fibrosis Canada show that more than 4,000 Canadian adults and children have the disease.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU